Navigation Links
New drug candidate reduces blood lipids
Date:3/10/2010

A thyroid-hormone-like substance that works specifically on the liver reduces blood cholesterol with no serious side effects. This according to a clinical trial conducted by researchers from the Swedish medical university Karolinska Institutet, amongst other centres, published today in the top-ranking scientific periodical The New England Journal of Medicine.

High cholesterol levels in the blood are primarily treated with a group of drugs called statins, but they are not always sufficiently effective and higher doses commonly cause adverse reactions. A team of researchers, including scientists from Karolinska Institutet, have now shown in a clinical trial that a new drug substance called eprotirome can reduce blood cholesterol effectively in patients who have already received statins. Patients who were given supplementary medication with eprotirome demonstrated levels of harmful blood fats that were up to 30 per lower than those of patients who received a placebo supplementary treatment.

The trial lasted three months and included a total of 189 patients. It remains to be studied whether the drug candidate will be equally safe and effective for a larger group of patients over a longer period of time.

"This drug could help patients who react adversely to statins or be used as a supplementary treatment for those who don't respond well to them," says Professor Bo Angelin, who led the study.

Eprotirome mimics the natural ability of thyroid hormone to stimulate the metabolism of cholesterol, and exerts its effects exclusively on the liver. The development of similar non-selective drugs has previously been stopped on account of the serious adverse effects they have had on other organ systems (e.g. cardiac dilatation and osteoporosis) or on the physiological regulation of thyroid hormones.

Eprotirome has been developed by pharmaceutical company KaroBio in Huddinge, which is financing and participating in the research.


'/>"/>

Contact: Katarina Sternudd
katarina.sternudd@ki.se
46-852-483-895
Karolinska Institutet
Source:Eurekalert

Related medicine news :

1. Addiction Industry Thrives Amidst Economic Climate, Seeks Certified Candidates
2. Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study
3. VHGI: VHGI Gold Targets Candidates to Fill Key Advisory Board Position to Evaluate International Mining Acquisitions; Internet Town Hall Meeting Details Emerge, Kitco Gold Coverage Initiated
4. Candidate Potential Report Reduces Risk of Bad Hires
5. Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology
6. Pitt researchers find candidates for new HIV drugs
7. AlphaRx Presents Company Overview and New Product Candidates at the Rodman Renshaw Healthcare Conference
8. EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 Auction
9. Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy
10. U.S. Senate Candidate Cheryle Jackson: Public Option Critical to Real Health Care Reform
11. DURECT Announces License of ADHD Drug Candidate in Selected Asian and South Pacific Countries to Orient Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... 26, 2016 , ... Catalent Pharma Solutions, the leading global ... and global clinical supply services, today announced two key appointments and the opening ... and strategic growth plans in the Asia Pacific region. , Howard Kim has ...
(Date:5/26/2016)... CA (PRWEB) , ... May 26, 2016 , ... In an effort to provide hair ... available to both Snapchat users and those who do not use the app. Dr. Mohebi, ... his new page, Dr. Mohebi Live . , Dr. Mohebi says, “The positive ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... for eating disorders, is opening a brand new child and adolescent residential treatment ... and their families with even more specialized eating disorder treatment and access to ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... multitude of activities from daily practices, arts & crafts, discussions, and games all ... East-D’Anna and Christy Evans have combined backgrounds in kids’ yoga, collegiate sport yoga ...
(Date:5/26/2016)... ... May 26, 2016 , ... Eugene Batelli, ... Along with his wonderful accolades and stellar patient reviews, Dr. Batelli continues to ... , Dr. Eugene Batelli is a highly trained Podiatric Surgeon who specializes in ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25,2016 FDA ... near-infrared Cellvizio platform for urological and surgical applications ... MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser ... milestone in the US with the 12 th ... Drug Administration (FDA). This new FDA clearance covers ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
(Date:5/25/2016)... According to market research "Global ... Demand Forecast to 2022 - Industry Insights by Type ... by P&S Market Research, the global insulin delivery device ... it is expected to grow at a CAGR of ... segment is expected to witness the fastest growth at ...
Breaking Medicine Technology: